3P innovation, which recently launched a new robotic filling machine capable of filling inhalers as well as capsules, says that it has started work on a new facility at Tournament Fields near Warwick, UK. The 30,000 sq ft facility, which is expected to be complete in the 4th quarter of 2018, will have room for expanded operations, including early development lab … [Read more...] about 3P Innovation to build new UK facility
News
FDA advisory committee votes against approval of Linhaliq
Aradigm Corporation said that the FDA's Antimicrobial Drugs Advisory Committee (ADAC) has voted against approval of the company's NDA for Linhaliq dual release inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in non-cystic fibrosis bronchiectasis (NCFBE) patients. The company submitted the NDA in July 2017, and the FDA granted the … [Read more...] about FDA advisory committee votes against approval of Linhaliq
Eurocine Vaccines announces Phase 1/2 study of Immunose Flu vaccine
Eurocine Vaccines has received authorization from the Swedish Medical Products Agency for a Phase 1/2 clinical study of its intranasal quadrivalent influenza vaccine Immunose Flu during the current flu season, the company said. Eurocine Vaccines also ran a Phase 1/2 study of Immunose Flu in 2016. Immunose Flu is based on the company's Endocine nasal vaccine … [Read more...] about Eurocine Vaccines announces Phase 1/2 study of Immunose Flu vaccine
Respimat gets Ease of Use Commendation from the Arthritis Foundation
Boehringer Ingelheim announced that its Respimat soft mist inhaler has received an Ease of Use Commendation from the Arthritis Foundation. In order to receive the commendation, products submitted by manufacturers to the Arthritis Foundation for consideration undergo assessment at the Intuitive Design Applied Research Institute. Arthritis Foundation Senior VP, … [Read more...] about Respimat gets Ease of Use Commendation from the Arthritis Foundation
FLUIDDA announces research collaboration with UCSF
Functional respiratory imaging specialist FLUIDDA has announced a new research collaboration with a team at the University of California, San Francisco led by Professor John Fahy that will use FLUIDDA technology "to understand the effects of pathologic mucus on lung function and on the deposition patterns of inhaled therapeutics." FLUIDDA CEO Jan De Backer said, … [Read more...] about FLUIDDA announces research collaboration with UCSF
3P Innovation launches new robotic capsule and device filler
3P Innovation has announced the launch of a new version of its R500 Robotic Capsule and Device Filler which is scalable and capable of filling inhalers directly as well as filling capsules. According to 3P, the filler can now be used for commercial production as well as for clinical development of both pure API inhalation powders and blended formulations. The … [Read more...] about 3P Innovation launches new robotic capsule and device filler
Nebulizer maker HCmed gets investment from Vivo Capital
Deepro nebulizer maker HCmed has announced that Vivo Capital's PANDA Fund has become a strategic investor as of December 27, 2017, saying, "As a healthcare focused investment firm, Vivo will fully support HCmed’s strategic plan to expand in the hand-held nebulizer markets to help relive [sic] global burden of respiratory disease, such as COPD, asthma and cystic … [Read more...] about Nebulizer maker HCmed gets investment from Vivo Capital
Savara appoints Peter Ginsberg as VP of Business Development
Inhaled drug developer Savara has announced the appointment of Peter Ginsberg as VP of Business Development. Ginsberg was most recently VP of Business Development at BioDelivery Sciences International and had previously held business development positions at a number of companies, including United Therapeutics and Surmodics. He also has experience as a biotechnology … [Read more...] about Savara appoints Peter Ginsberg as VP of Business Development
Liquidia announces initiation of Phase 3 trial of trepostinil DPI for PAH
A Phase 3 trial of Liquidia Technologies' LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) is underway, the company said. The study is expected to enroll a minimum of 100 PAH patients in the US, with topline data anticipated in 2019. LIQ861, a dry powder formulation based on Liquidia’s PRINT particle engineering technology, is one … [Read more...] about Liquidia announces initiation of Phase 3 trial of trepostinil DPI for PAH
OraPharma to co-promote Sprix nasal spray in the US
Egalet Corporation has terminated a co-promotion agreement with Septodont, the company said, and is now partnered with Valeant's OraPharma division for co-promotion of Sprix ketorolac tromethamine nasal spray to US dentists and oral surgeons. Sprix has been approved by the FDA since 2010 for short-term treatment of moderate-to-severe pain. Under the terms of the … [Read more...] about OraPharma to co-promote Sprix nasal spray in the US